Home / Resources / Videos / ADA 2017 / Thomas Seck Part 4, Empagliflozin Effects on Cardiovascular Disease

Thomas Seck Part 4, Empagliflozin Effects on Cardiovascular Disease




In part 4 of this Exclusive Interview, Dr. Thomas Seck shares his thought about Empagliflozin effects on cardiovascular disease and Empagliflozin as it relates to diabetes professionals in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

Thomas Seck, MD, is VP of Clinical Development and Medical Affairs at Boehringer Ingelheim.

Transcript of this video segment:

Steve: If you were presenting to the mass audience to the medical professionals involved in diabetes care and you were talking to nurses and pharmacists and dietitians and PCPs, and you are talking about Empagliflozin. What would you say to them?

Dr. Seck: I would say to them that this drug Empagliflozin Jardiance is really a new breakthrough medication. Because for the first time with diabetes medication, we have an associated effect on cardiovascular death. Its not a small effect, it’s a sizable effect: 38%. Which really changes and should change moving forward the way we manage patients with type 2 diabetes in with cardiovascular disease. And in that context, obviously Jardiance has been glucose lowering medication. Now with the indication received by the FDA in December of last year, to reduce the risk of cardiovascular death what you also need to consider beside glucose is cardiovascular risk. I think having that at the forefront of making decisions, especially in population where you have diabetes and established cardiovascular disease, I think it will really change how we think about the disease. Because in a lot of ways, you could argue that this medication provides value independent of glucose reduction. So if you have a patient that you believe is already controlled based on HbA1c levels, but has a high risk of cardiovascular disease if that patient had a stroke or had a MI previously and has type 2 diabetes, there is still the value of reducing the risk for cardiovascular death. That really is a change in mindset on when to use drug such as Jardiance.

Return to the main page.